Asia Pacific Rapid Diagnostic Testing Kits Market is segmented By Technology (Lateral Flow Assay, Agglutination Assay, Flow-through, Dipstick Assay (Solid-phase), Microfluidic chips, Others), By Application (Glucose Monitoring, Cardiometabolic Testing, Infectious Disease Testing, Drugs of Abuse Testing, Others), By End User (Hospitals and Clinics, Diagnostic Centers, Homecare, Others) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Market Size
The Asia-Pacific rapid diagnostic testing kits market reached US$ 4.30 billion in 2023 and is expected to reach US$ 8.12 billion by 2031, growing at a CAGR of 8.4% during the forecast period 2024-2031.
A rapid diagnostic test (RDT) is a medical diagnostic test that is quick and easy to perform. RDTs are suitable for preliminary or emergency medical screening and for use in medical facilities with limited resources. They also allow point-of-care testing in primary care for things that formerly only a laboratory test could measure. They provide same-day results within two hours, typically in approximately 20 minutes.
Rapid diagnostics are based on the same immunochromatographic technology as standard home pregnancy tests. Most rapid diagnostics use blood from finger pricks (although venous blood works). In general, rapid diagnostics offer comparable sensitivity to smear microscopy with much less interobserver variability. Their principle is to capture antibodies on a solid surface where complementary antigens are attached. Different technologies are used, like immune chromatography, lateral flow tests, and cassettes. There is a control line that can confirm the correct liquid migration.
Market Scope
| Metrics | Details |
| CAGR | 8.4% |
| Market Size | 2022-2031 |
| Market Estimation Forecast Period | 2024-2031 |
| Revenue Units | Value (US$ Mn) |
| Segments Covered | Technology, Application, and End-User |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter's Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis, and Other key Insights. |
For more details on this report - Request for Sample
Market Dynamics: Drivers
Increasing prevalence of chronic infectious and non-infectious diseases
The rising prevalence of various medical conditions propels the market growth. For instance, according to the estimates posted by unaids.org in 2023, there are 25,00,000 adults and children living with HIV in India. There are 68,000 adults and children newly infected in the previously mentioned statistics. There are 36,000 deaths due to AIDS in 2023. The prevalence rate is 0.3. Moreover, according to the estimates posted by unaids.org in 2023, there are 2,90,000 adults and children living with HIV in Pakistan. There are 11,000 deaths in Pakistan due to AIDS.
And the anti-retroviral therapy coverage in Pakistan is 99.2%. The HIV prevalence percentage in Pakistan is 2%. The anti-retroviral therapy coverage in India is 70%. For instance, according to the estimates posted by unaids.org in 2023, there are 76,000 adults and children living with HIV in Cambodia. The anti-retroviral therapy coverage in Cambodia is 100%. There are 1,200 adults and children newly infected in the previously mentioned statistics.
Restraints
Factors such as lack of healthcare infrastructure, lack of awareness among people, shortage of skilled professionals, and stringent regulatory requirements for the approval of new techniques are expected to hamper the market.
Market Segment Analysis
The Asia Pacific rapid diagnostic testing kits market is segmented based on technology, application, and end-user.
The segment infectious disease testing accounted for approximately 56.6% of the Asia Pacific rapid diagnostic testing kits market share
The infectious disease testing segment is expected to hold the largest market share over the forecast period. In this segment, the development of government regulation, and rising funds for private manufacturers for research works would drive this market.
For instance, in June 2023, to improve the offering in the in vitro diagnostics (IVD) field, Bengaluru-based startup GenWorks announced the launch of its IVD tests including rapid card test kits for dengue and malaria. The use of IVD products for dengue and malaria is aimed at preventing, diagnosing, curing, and treating seasonal epidemics and mitigating their impact.
Moreover, according to an article published by the Times of India in June 2024, India saw a striking 122% surge in dengue cases and a 16% increase in those of malaria in a year, underlining a persistent rise in vector-borne diseases, which pose a growing threat. The economic survey report underscored the continued increase in reported cases of infectious diseases like leprosy and TB.
Market Segmentation
By Technology
- Lateral Flow Assay
- Agglutination Assay
- Flow-through
- Dipstick Assay (Solid-phase)
- Microfluidic chips
- Others
By Application
- Glucose Monitoring
- Cardiometabolic Testing
- Infectious Disease Testing
- Drugs of Abuse Testing
- Others
By End-User
- Hospitals and Clinics
- Diagnostic Centers
- Homecare
- Others
Market Competitive Landscape
The major players in the Asia Pacific rapid diagnostic testing kits market include Merck KGaA, Thermo Fisher Scientific Inc., Abbott, Beckman Coulter Inc., Bio-Rad Laboratories Inc., Creative Diagnostics, Becton, Dickinson and Company, Goldsite Diagnostics Inc., InTec Products Inc., Protia Inc. among others.
Key Developments
- In February 2023, Pune-based Mylab Discovery Solutions launched three new rapid kits for the early and fast detection of sexually transmitted infections (STIs) such as Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), and Syphilis. These infections pose a major health challenge as World Health Organisation (WHO) estimates say that the daily caseload of STIs is set to reach 1 million per day globally.
- In July 2023, in a bid to reduce the life-threatening complications and consequences associated with tuberculosis (TB), EMPE Diagnostics launched its one-of-its-kind test kit mfloDx™ MDR-TB at Telangana Lifesciences office, in Hyderabad.
Why Purchase the Report?
- To visualize the Asia Pacific rapid diagnostic testing kits market segmentation based on technology, application, and end-user as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development
- Excel data sheet with numerous data points of Asia Pacific rapid diagnostic testing kits market level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping is available in Excel consisting of key products of all the major players.
The Asia Pacific rapid diagnostic testing kits market report would provide approximately 51 tables, 54 figures, and 181 Pages.
Target Audience 2024
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
